- Home
- SMID vs PLX Comparison
SMID vs PLX Comparison
Compare SMID & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMID
- PLX
- Stock Information
- Founded
- SMID 1960
- PLX 1993
- Country
- SMID United States
- PLX United States
- Employees
- SMID N/A
- PLX N/A
- Industry
- SMID Building Materials
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SMID Industrials
- PLX Health Care
- Exchange
- SMID Nasdaq
- PLX Nasdaq
- Market Cap
- SMID 157.4M
- PLX 127.4M
- IPO Year
- SMID 1995
- PLX 1998
- Fundamental
- Price
- SMID $37.10
- PLX $1.55
- Analyst Decision
- SMID
- PLX Strong Buy
- Analyst Count
- SMID 0
- PLX 1
- Target Price
- SMID N/A
- PLX $15.00
- AVG Volume (30 Days)
- SMID 10.1K
- PLX 539.9K
- Earning Date
- SMID 07-10-2025
- PLX 08-13-2025
- Dividend Yield
- SMID N/A
- PLX N/A
- EPS Growth
- SMID 444.88
- PLX N/A
- EPS
- SMID 1.86
- PLX 0.05
- Revenue
- SMID $84,450,000.00
- PLX $59,764,000.00
- Revenue This Year
- SMID N/A
- PLX $10.00
- Revenue Next Year
- SMID N/A
- PLX $83.13
- P/E Ratio
- SMID $20.45
- PLX $31.35
- Revenue Growth
- SMID 33.01
- PLX 0.18
- 52 Week Low
- SMID $25.13
- PLX $0.82
- 52 Week High
- SMID $51.96
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- SMID 54.68
- PLX 51.65
- Support Level
- SMID $36.06
- PLX $1.41
- Resistance Level
- SMID $38.92
- PLX $1.56
- Average True Range (ATR)
- SMID 1.56
- PLX 0.06
- MACD
- SMID -0.19
- PLX 0.01
- Stochastic Oscillator
- SMID 64.40
- PLX 47.83
About SMID Smith-Midland Corporation
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.